JAEA
  • help
  • PC | SP
  • JP | EN
          
検索対象：     
報告書番号：
※ 半角英数字
 年 ～ 
 年
全てクリア
検索結果：　118 件中 1件目～20件目を表示

発表形式

Initialising ...

選択項目を絞り込む

掲載資料名

Initialising ...

発表会議名

Initialising ...

筆頭著者名

Initialising ...

キーワード

Initialising ...

使用言語

Initialising ...

発行年

Initialising ...

開催年

Initialising ...

選択した検索結果をダウンロード

論文

Rational evaluation of the therapeutic effect and dosimetry of auger electrons for radionuclide therapy in a cell culture model

篠原 彩花*; 花岡 宏史*; 坂下 哲哉*; 佐藤 達彦; 山口 藍子*; 石岡 典子*; 対馬 義人*

Annals of Nuclear Medicine, 32(2), p.114 - 122, 2018/02

https://doi.org/10.1007/s12149-017-1225-9
 被引用回数：8 パーセンタイル：41.11(Radiology, Nuclear Medicine & Medical Imaging)

オージェ放出核種を用いた放射線治療は、高い治療効果と低い正常組織反応を期待できる。本研究では、オージェ放出核種$$^{125}$$Iと$$beta$$線放出核種$$^{131}$$Iを2次元と3次元の培養細胞に取り込ませて、その細胞致死率を測定した。また、粒子・重イオン輸送計算コードPHITSを用いて、各条件に対する細胞の吸収線量分布を精度よく計算し、細胞生存率と吸収線量の関係について評価した。その結果、$$^{125}$$I治療は$$^{131}$$I治療と比較して、2次元培養細胞の場合はほぼ同程度の効果が得られるが、3次元培養細胞の場合は治療効果が低いことが分かった。これは、クロスファイア効果と呼ばれる一本の$$beta$$線が複数の細胞をヒットする効果と、薬剤が培養細胞内に均一に分布しない効果に起因すると考えられる。

論文

Medical application of radiohalogenated peptides; Synthesis and ${it in vitro}$ evaluation of F(${it p}$-$$^{131}$$I)KCCYSL for targeting HER2

佐々木 一郎; 渡辺 茂樹; 大島 康宏; 須郷 由美; 山田 圭一*; 花岡 宏史*; 石岡 典子

Peptide Science 2015, p.243 - 246, 2016/03

Radioisotope labeled peptides with high affinity to receptors overexpressing on the surface of tumor cells are promising for applications in nuclear medicine such as diagnostic radiography and radiotherapy. Radiohalogens such as $$^{131}$$I and $$^{211}$$At are useful for clinical imaging and therapeutic applications, and it can be introduced at the ${it para}$ position of phenylalanine residue via electrophilic destannylation. KCCYSL (Lys$$^{1}$$-Cys$$^{2}$$-Cys$$^{3}$$-Tyr$$^{4}$$-Ser$$^{5}$$-Leu$$^{6}$$) is a hexapeptide containing disulfide bond. Previous study revealed that KCCYSL has potential as tumor imaging and therapeutic agent targeting tumor cells overexpressing the human epidermal growth factor receptor type 2 (HER2). In this study, we report synthesis and ${it in vitro}$ evaluation of radiohalogenated KCCYSL derivatives. Precursor peptides, Boc-F(${it p}$-SnBu$$_{3}$$)K(Boc)C(Trt)C(Trt)Y($$^{t}$$Bu)S($$^{t}$$Bu)L-OH and Boc-F(${it p}$-SnBu$$_{3}$$)GS($$^{t}$$Bu)GK(Boc)C(Trt)C(Trt)Y($$^{t}$$Bu)S($$^{t}$$Bu)L-OH, were synthesized by the Fmoc solid phase peptide synthesis. Then, precursor peptides were radioiodinated via electrophilic destannylation, and they were deprotected to obtain F(${it p}$-$$^{131}$$I)KCCYSL and F(${it p}$-$$^{131}$$I)GSGKCCYSL in radiochemical yield 15% and 17%, respectively. ${it In vitro}$ assays of the radioiodinated peptides for HER2 and stability in serum are being undertaken.

論文

Development of a widely usable amino acid tracer; $$^{76}$$Br-$$alpha$$-methyl-phenylalanine for tumor PET imaging

花岡 宏史*; 大島 康宏; 鈴木 結利花*; 山口 藍子*; 渡辺 茂樹; 上原 知也*; 永森 收志*; 金井 好克*; 石岡 典子; 対馬 義人*; et al.

Journal of Nuclear Medicine, 56(5), p.791 - 797, 2015/05

https://doi.org/10.2967/jnumed.114.152215
 被引用回数：19 パーセンタイル：62.77(Radiology, Nuclear Medicine & Medical Imaging)

Radiolabeled amino acids are superior PET tracers for imaging of malignant tumors, and amino acids labeled with $$^{76}$$Br, an attractive positron emitter due to its relatively long half-life (t$$_{1/2}$$=16.2 h), could potentially be widely usable tumor imaging tracer. In this study, in consideration of stability and tumor specificity, 2-$$^{76}$$Br-bromo-$$alpha$$-methyl-L-phenylalanine (2-$$^{76}$$Br-BAMP) and 4-$$^{76}$$Br-bromo-$$alpha$$-methyl-L-phenylalanine (4-$$^{76}$$Br-BAMP) were designed and their potential as a tumor imaging agent was evaluated. No-carrier-added $$^{76}$$Br and $$^{77}$$Br, the latter of which is suitable radiobromine for basic studies due to its longer half-life (t$$_{1/2}$$ = 57.1 h), were produced. Both $$^{77}$$Br-BAMPs were stable in the plasma and in the murine body. In biodistribution studies, 2-$$^{77}$$Br-BAMP showed more rapid blood clearance and lower renal accumulation than did 4-$$^{77}$$Br-BAMP. More than 90% of injected radioactivity was excreted in the urine by 6 h post-injection of 2-$$^{77}$$Br-BAMP. High tumor accumulation of 2-$$^{77}$$Br-BAMP was observed in tumor-bearing mice and PET imaging with 2-$$^{76}$$Br-BAMP enabled clear visualization of the tumor. These findings suggest that 2-$$^{76}$$Br-BAMP would constitute a potential new PET tracer for tumor imaging and may eventually enable the wider use of amino acid tracers.

論文

Exploring of peptides with affinity to HER2 from random peptide libraries using radioisotope; Random hexapeptide libraries with fixed amino acid sequence at 1 and 2 positions

佐々木 一郎; 花岡 宏史*; 山田 圭一*; 渡辺 茂樹; 須郷 由美; 大島 康宏; 鈴木 博元; 石岡 典子

Peptide Science 2014, p.257 - 260, 2015/03

We have sought to establish drug discovery system using radioisotope (RI) labeled peptides which have high affinity to target proteins overexpressed in cancers. Of the target proteins, we chose the human epidermal growth factor receptor type 2 (HER2), a membrane protein overexpressed in various cancers to evaluate the drug discovery system. Three series of random hexapeptide libraries introduced a radioiodinated D-tyrosine (y(3-$$^{131}$$I)) to $$N$$-terminal were designed and binding assay with HER2-expressed cell lines were conducted in this study. First, we synthesized a series of random hexapeptide libraries with fixed amino acid sequence at 1 and 2 positions, y(3-$$^{131}$$I)X$$^{1}$$X$$^{2}$$X$$^{3}$$X$$^{4}$$X$$^{5}$$X$$^{6}$$. Non-radioactive random peptide libraries, yXXXXXX, were prepared by Fmoc-SPPS with an automatic peptide synthesizer. Radioiodinated y(3-$$^{131}$$I)XXXXXX were subsequently synthesized in 30-50% radiochemical yield. Binding assay using HER2-overexpressed cell line showed that high affinity (38-50% dose, n=6) was obtained with yIIXXXX, while other random peptide libraries were yielded low affinity (approximately 1% dose), which indicated that the system using RI labeled random peptide libraries have potential to discover peptide drug for cancer therapy. Preparation of other random hexapeptide libraries are being undertaken.

論文

Production of highly purified no-carrier-added $$^{177}$$Lu for radioimmunotherapy

渡辺 智; 橋本 和幸; 渡辺 茂樹; 飯田 靖彦*; 花岡 宏史*; 遠藤 啓吾*; 石岡 典子

Journal of Radioanalytical and Nuclear Chemistry, 303(1), p.935 - 940, 2015/01

https://doi.org/10.1007/s10967-014-3534-y
 被引用回数：14 パーセンタイル：73.72(Chemistry, Analytical)

No-carrier-added $$^{177}$$Lu produced via the $$^{176}$$Yb(n, $$gamma$$) $$^{177}$$Yb $$rightarrow$$$$^{177}$$Lu process was separated from the macroscopic amounts of the Yb target using reversed-phase ion-pair liquid chromatography. To produce a highly purified $$^{177}$$Lu solution capable of labeling antibodies, the metallic impurities were removed using cation, chelating ion, and anion exchange columns. After the elimination of metallic impurities, the concentrations of Ca, Fe, and Zn were reduced from 87, 340, and 77 ppb to 13, 18, and 9 ppb, respectively. Consequently, the labeling yield of the $$^{177}$$Lu -labeled antibody increased from less than 5% to 88%.

論文

Synthesis of radiohalogen-labeled peptide with high affinity to HER2/neu receptor

佐々木 一郎; 山田 圭一*; 渡辺 茂樹; 花岡 宏史*; 須郷 由美; 奥 浩之*; 石岡 典子

JAEA-Review 2013-059, JAEA Takasaki Annual Report 2012, P. 96, 2014/03

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2013-059.pdf

Radioisotope (RI)-labeled peptide with high affinity to receptors overexpressing on the surface of tumor cells are promising for applications in nuclear medicine such as diagnostic radiography and radiotherapy. MARSGL (H-Met$$^{1}$$-Ala$$^{2}$$-Arg$$^{3}$$-Ser$$^{4}$$-Gly$$^{5}$$-Leu$$^{6}$$-OH), a linear peptide consisting of six amino acids, has high affinity to HER2/neu receptor overexpressing in various cancer cells. Radiohalogens (radionuclides) such as radioiodine and radiobromine are versatile for clinical imaging and therapeutic applications. Thus, radiohalogenated MARSGL may have potential for clinical applications to HER2 overexpressing tumors. In this study, in order to achieve the labeling of radiohalogen for MARSGL, we design a radioiodinated peptide, F(${it p}$-$$^{131}$$I)MARSGL, in which phenylalanine labeled with $$^{131}$$I (t$$_{1/2}$$ = 8.0 d) at the ${it para}$ position of the aromatic ring is introduced into the N-terminal of MARSGL and report a new technique to prepare radiohalogen of peptide via electrophilic destanylation.

論文

Biological evaluation of 3-[$$^{18}$$F]fluoro-$$alpha$$-methyl-D-tyrosine (D-[$$^{18}$$F]FAMT) as a novel amino acid tracer for positron emission tomography

大島 康宏; 花岡 宏史*; 富永 英之*; 金井 好克*; 解良 恭一*; 山口 藍子*; 永森 收志*; 織内 昇*; 対馬 義人*; 遠藤 啓吾*; et al.

Annals of Nuclear Medicine, 27(4), p.314 - 324, 2013/05

https://doi.org/10.1007/s12149-013-0687-7
 被引用回数：15 パーセンタイル：48.78(Radiology, Nuclear Medicine & Medical Imaging)

Since D-amino acid is not distributed much in the non-target organs and is rapidly excreted in the urine, radiotracer using D-amino acid would allow clear PET image of the tumor early after administration. In this study, we prepared 3-[$$^{18}$$F]fluoro-$$alpha$$-methyl-D-tyrosine (D-[$$^{18}$$F]FAMT) and evaluated its usefulness. In biodistribution studies, D-[$$^{18}$$F]FAMT showed rapid clearance from the blood, marked accumulation and retention in the tumor and low accumulation in non-target organs. The amount of D-[$$^{18}$$F]FAMT in the tumor was also lowered, tumor-to-blood ratio and tumor-to-muscle ratio of D-[$$^{18}$$F]FAMT were similar to those of correspondign L-isomer, 3-[$$^{18}$$F]fluoro-$$alpha$$-methyl-L-tyrosine (L-[$$^{18}$$F]FAMT), at every timepoint. Consequently, PET imaging with D-[$$^{18}$$F]FAMT could not show clear image of the tumor early after the administration. However, D-[$$^{18}$$F]FAMT enabled higher tumor-to-background contrast than L-[$$^{18}$$F]FAMT. In conclusions, D-[$$^{18}$$F]FAMT showed rapid blood clearance, low accumulation in non-target organs, and tumor-selective image compared with L-[$$^{18}$$F]FAMT. Thus, D-[$$^{18}$$F]FAMT could potentially serve as a novel PET tracer for imaging malignant tumors.

論文

Synthesis of radiohalogen-labeled peptides with high affinity to HER2/neu receptor

佐々木 一郎; 山田 圭一*; 渡邉 茂樹; 花岡 宏史*; 須郷 由美; 奥 浩之*; 石岡 典子

Peptide Science 2013, p.157 - 160, 2013/03

Radioisotope (RI)-labeled peptides which have the high affinity to receptors on surface of the tumor cell are promising for diagnostic radiography (PET and SPECT) and radiotherapy. MARSGL (H-Met$$^{1}$$-Ala$$^{2}$$-Arg$$^{3}$$-Ser$$^{4}$$-Gly$$^{5}$$-Leu$$^{6}$$-OH), a linear hexapeptide consisting of six amino acids, has the high affinity to HER2/neu receptor overexpressing in various cancer cells. Thus, radiolabeled MARSGL has potential for the above mentioned purposes. Radiohalogens have various useful radionuclides, which could be introduced to aromatic compounds via tin-halogen exchange reaction. In this study, stannylated peptide Boc-F(${it p}$-SnBu$$_{3}$$)MAR(Pbf)S($$^{t}$$Bu)GL-OH was synthesized to prepare radiohalogen ($$^{76}$$Br or $$^{131}$$I)-labeled FMARSGL derivatives. First, Boc-Phe(${it p}$-SnBu$$_{3}$$)-OH was prepared from Boc-Phe(${it p}$-I)-OMe via Pd(0)-catalyzed coupling reaction with (Bu$$_{3}$$Sn)$$_{2}$$ and was successfully introduced into ${it N}$-terminal of H-MARSGL-Trt(2-Cl) resin synthesized from H-Leu-Trt(2-Cl) resin by Fmoc-SPPS. After cleavage reaction of Boc-F(${it p}$-SnBu$$_{3}$$)MAR(Pbf)S($$^{t}$$Bu)GL-Trt(2-Cl) resin with 25% 1,1,1,3,3,3-hexafluoro-2-propanol in CH$$_{2}$$Cl$$_{2}$$, Boc-F(${it p}$-SnBu$$_{3}$$)MAR(Pbf)S($$^{t}$$Bu)GL-OH was obtained and identified by using ESI-MS and NMR. Synthesis of $$^{131}$$I-labeled FMARSGL is due to report in this presentation.

論文

Development of a $$^{76}$$Br-labeled amino acid derivative for PET imaging of tumor

花岡 宏史*; 渡邉 茂樹; 富永 英之*; 大島 康宏; 渡辺 智; 山田 圭一*; 飯田 靖彦*; 石岡 典子; 遠藤 啓吾*

JAEA-Review 2012-046, JAEA Takasaki Annual Report 2011, P. 89, 2013/01

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2012-046.pdf

近年、がんに対する特異性が高いPET薬剤として、$$^{11}$$Cや$$^{18}$$Fで標識したアミノ酸誘導体が開発され、臨床応用されるようになってきた。しかしながら$$^{11}$$Cや$$^{18}$$Fは半減期が非常に短いため、それぞれの病院で製造・合成する必要があり、限られた施設でしか使えないのが現状である。一方、$$^{76}$$Brは、半減期が16.1時間とポジトロン放出核種としては比較的長く、またハロゲン核種であるため母体化合物との結合にキレート剤等が必要ないことから、アミノ酸のような低分子化合物に対しても応用可能である。そこで本研究では、広く臨床使用することが可能な、新規がん診断用PETイメージング薬剤として$$^{76}$$Br標識アミノ酸誘導体の開発を計画した。基礎検討には半減期が長い放射性臭素である$$^{77}$$Br(半減期57時間)を用いて行うこととした。Br標識アミノ酸としては、$$alpha$$メチルフェニルアラニン($$alpha$$-Me-Phe)のパラ位にBrを導入したBr-$$alpha$$-Me-Pheを設計した。$$^{77}$$Br-$$alpha$$-Me-Pheは標識率25-40%で合成することができた。$$^{77}$$Br-$$alpha$$-Me-Pheを担癌マウスに投与したところ、腫瘍への高い集積性を示し、投与3時間後の腫瘍対血液比は3.94、腫瘍対筋肉比は3.95であった。$$^{76}$$Br-$$alpha$$-Me-Pheを担癌マウスに投与してPET撮像を行ったところ、腫瘍を明瞭に描出することができた。以上の結果から、$$^{76}$$Br-$$alpha$$-Me-Pheの新規がんイメージング薬剤としての有用性が示唆された。

論文

Synthesis of radioiodinated antitumor cyclic peptide, [$$^{125}$$I]-sansalvamide A derivative

渡邉 茂樹; 山田 圭一*; 津久井 匠隆*; 花岡 宏史*; 大島 康宏; 山口 藍子*; 奥 浩之*; 石岡 典子

JAEA-Review 2012-046, JAEA Takasaki Annual Report 2011, P. 88, 2013/01

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2012-046.pdf

Sansalvamide A (SA), a penta cyclic peptide isolated marine fungus, is a lead compound of anti-cancer reagent because the peptide has cytotoxicity against various cancer cell lines. Halogenated SA derivatives (SA-X, X = Cl, Br, I) was prepared and remarkable cytotocity against malignant human breast cancer. In this study, a radiohalogenated SA derivative [$$^{125}$$I]SA-I was prepared to conduct in vivo evaluation of SA derivatives. Synthetic scheme of [$$^{125}$$I]SA-I are as follows: an iodinated linear peptide, Boc-F(p-I)LLVL-OMe, was prepared by the conventional solid phase peptide synthesis. After preparation of stannylated peptide, Boc-F(p-SnBu$$_{3}$$)LLVL-OMe, $$^{125}$$I was labeled with electrophilic destannylation in the presence of oxidizing reagent. After deprotection of N- and C-termius, [$$^{125}$$I]SA-I was obtained successfully by macrocyclization in liquid phase. Overall labeled yield was 7%. To our best knowledge, this report is the first on the synthesis of radiolabeled SA derivative. In vivo evaluation of the SA derivative using [$$^{125}$$I]SA-I is being undertaken.

論文

Predicting cetuximab accumulation in ${it KRAS}$ wild-type and ${it KRAS}$ mutant colorectal cancer using $$^{64}$$Cu-labeled cetuximab positron emission tomography

Achmad, A.*; 花岡 宏史*; 吉岡 弘樹*; 山元 進司*; 富永 英之*; 荒木 拓也*; 大島 康宏; 織内 昇*; 遠藤 啓吾*

Cancer Science, 103(3), p.600 - 605, 2012/03

https://doi.org/10.1111/j.1349-7006.2011.02166.x
 被引用回数：27 パーセンタイル：57.49(Oncology)

Overexpression of epidermal growth factor receptor (EGFR) is common in colorectal cancer. However, cetuximab, an EGFR-targeting drug, is useful only for a subset of patients and no single predictor other than V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (${it KRAS}$) mutation status has been established. In this study, we investigated cetuximab accumulation in colorectal tumors using $$^{111}$$In-DOTA-cetuximab, and evaluated the potential of positron emission tomography (PET) imaging of $$^{64}$$Cu-DOTA-cetuximab. We found that ${it KRAS}$ wild-type tumors had significantly higher $$^{111}$$In-DOTA-cetuximab accumulation than ${it KRAS}$ mutant tumors. Based on ${it KRAS}$ mutation status, a strong correlation was found between $$^{111}$$In-DOTA-cetuximab tumor uptake and EGFR expression level. Significant correlation was also found between tumor uptake of $$^{111}$$In-DOTA-cetuximab and $$^{64}$$Cu-DOTA-cetuximab. PET imaging with $$^{64}$$Cu-DOTA-cetuximab effectively visualized cetuximab accumulation in colorectal tumors with a wide variety of EGFR expression levels and different ${it KRAS}$ mutation status as commonly encountered in the clinical setting. Our findings suggest that this radioimmunoimaging can be clinically translated as an in vivo tool to predict cetuximab accumulation in colorectal cancer patients prior to cetuximab therapy.

論文

Preparation and biological evaluation of 3-[$$^{76}$$Br]bromo-$$alpha$$-methyl-L-tyrosine, a novel tyrosine analog for PET imaging of tumors

大島 康宏; 花岡 宏史*; 渡邉 茂樹; 須郷 由美; 渡辺 智; 富永 英之*; 織内 昇*; 遠藤 啓吾*; 石岡 典子

JAEA-Review 2011-043, JAEA Takasaki Annual Report 2010, P. 91, 2012/01

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2011-043.pdf

3-[$$^{18}$$F]Fluoro-$$alpha$$-methyl-L-tyrosine ([$$^{18}$$F]FAMT) is a useful amino acid tracer for PET imaging of malignant tumors. FAMT analogs labeled with $$^{76}$$Br, a positron emitter with a long half-life (t$$_{1/2}$$=16.1 h), could be widely used as tracers for tumor imaging. In this study, 3-[$$^{76}$$Br]bromo-$$alpha$$-methyl-L-tyrosine ([$$^{76}$$Br]BAMT) was designed, and its usefulness was evaluated as a novel PET tracer for imaging malignant tumors. In this study, both [$$^{76}$$Br]BAMT and [$$^{77}$$Br]BAMT were prepared. [$$^{77}$$Br]BAMT was stable in vitro, but was catabolized after administration in mice. Cellular accumulation and retention of [$$^{77}$$Br]BAMT using LS180 colon adenocarcinoma cells were significantly higher than those of [$$^{18}$$F]FAMT. In biodistribution studies using LS180 tumor-bearing mice, the tumor accumulation of [$$^{77}$$Br]BAMT was higher than that of [$$^{18}$$F]FAMT. However, some level of debromination was seen, and this debromination caused more retention of radioactivity in the blood and organs than was seen with [$$^{18}$$F]FAMT. PET imaging with [$$^{76}$$Br]BAMT enabled clear visualization of the tumor. In conclusion, although an improvement in stability is still needed, $$^{76}$$Br-labeled FAMT analogs could potentially serve as PET tracers for the imaging of malignant tumors.

論文

Production of radioactive bromine $$^{76}$$Br

渡辺 智; 渡邉 茂樹; 飯田 靖彦*; 花岡 宏史*; 遠藤 啓吾*; 石岡 典子

JAEA-Review 2011-043, JAEA Takasaki Annual Report 2010, P. 92, 2012/01

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2011-043.pdf

現在PET診断に用いられている核種は半減期が2時間以下と非常に短いため、抗体のような集積に時間のかかる化合物を利用したPET診断には限界がある。これを解決するために、本研究では新規ポジトロン放出核種として半減期が16.2時間の$$^{76}$$Brの製造法の開発を行った。セレン化銅をターゲットとし、$$^{76}$$Se(p,n) $$^{76}$$Br反応を用い、原子力機構のTIARA-AVFサイクロトロンからの20MeV, H$$^{+}$$ビームで照射をして$$^{76}$$Brを生成した。$$^{76}$$Brの回収にはターゲット由来の毒物であるSeの混入を防ぐために乾式蒸留法を採用し、Brトラップ回収条件等の検討により、$$^{76}$$Brの高純度分離を達成した。分離条件については、回収方法及び電気炉内温度の最適化により、ターゲット中に生成した全$$^{76}$$Brの放出及びテフロンチューブ内でのロスの低減により、30%程度の回収率を約80%にまで向上させることに成功した。

論文

Preparation and biological evaluation of 3-[$$^{76}$$Br]bromo-$$alpha$$-methyl-L-tyrosine, a novel tyrosine analog for positron emission tomography imaging of tumors

大島 康宏; 花岡 宏史*; 渡邉 茂樹; 須郷 由美; 渡辺 智; 富永 英之*; 織内 昇*; 遠藤 啓吾*; 石岡 典子

Nuclear Medicine and Biology, 38(6), p.857 - 865, 2011/08

https://doi.org/10.1016/j.nucmedbio.2011.02.001
 被引用回数：14 パーセンタイル：46.62(Radiology, Nuclear Medicine & Medical Imaging)

3-[$$^{18}$$F]fluoro-$$alpha$$-methyl-L-tyrosine ([$$^{18}$$F]FAMT) is a useful amino acid tracer for positron emission tomography (PET) imaging of malignant tumors. FAMT analogs labeled with $$^{76}$$Br, a positron emitter with a long half-life ($$t$$$$_{1/2}$$=16.1 h), could be widely used as tracers for tumor imaging. In this study, 3-[$$^{76}$$Br]bromo-$$alpha$$-methyl-L-tyrosine ([$$^{76}$$Br]BAMT) was designed, and its usefulness was evaluated as a novel PET tracer for imaging malignant tumors. In this study, both [$$^{76}$$Br]BAMT and [$$^{77}$$Br]BAMT were prepared. [$$^{77}$$Br]BAMT was stable in vitro, but was catabolized after administration in mice. Cellular accumulation and retention of [$$^{77}$$Br]BAMT using LS180 colon adenocarcinoma cells were significantly higher than those of [$$^{18}$$F]FAMT. In biodistribution studies using LS180 tumor-bearing mice, the tumor accumulation of [$$^{77}$$Br]BAMT was higher than that of [$$^{18}$$F]FAMT. However, some level of debromination was seen, and this debromination caused more retention of radioactivity in the blood and organs than was seen with [$$^{18}$$F]FAMT. PET imaging with [$$^{76}$$Br]BAMT enabled clear visualization of the tumor. In conclusion, although an improvement in stability is still needed, $$^{76}$$Br-labeled FAMT analogs could potentially serve as PET tracers for the imaging of malignant tumors.

論文

褐色細胞腫の新しいPET診断薬剤; $$^{76}$$Br-MBBG

石岡 典子; 渡邉 茂樹; 花岡 宏史*

内分泌画像検査・診断マニュアル, p.218 - 219, 2011/04

「内分泌画像検査・診断マニュアル」は、画像検査に関する実践的なマニュアルとして、内分泌系の系統別,疾患別に画像検査の目的,前処置,実施方法,結果の評価,副作用と対処法などをコンパクトにまとめかつ可能な限り多くの画像を掲載し、内分泌代謝疾患の診療に従事するすべての医師を対象として、いずれの施設でもこれまで以上に内分泌疾患の診断が円滑に実施できることを最大の目的として出版される。第8章「新しい画像検査」において、RI医療応用研究グループで開発した内分泌疾患のPET検査を可能にする新しいRI薬剤、$$^{76}$$Br-MBBGについて、臨床医のためのポイントも含め解説する。

論文

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with $$^{64}$$Cu -labeled trastuzumab PET

Paudyal, P.*; Paudyal, B.*; 花岡 宏史*; 織内 昇*; 飯田 靖彦*; 吉岡 弘樹*; 富永 英之*; 渡辺 智; 渡邉 茂樹; 石岡 典子; et al.

JAEA-Review 2010-065, JAEA Takasaki Annual Report 2009, P. 108, 2011/01

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2010-065.pdf

Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of $$^{64}$$Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with $$^{64}$$Cu-DOTA-trastuzumab. PET studies revealed a significantly high accumulation of $$^{64}$$Cu-DOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 h and 48 h post-injection. $$^{64}$$Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy.

論文

Production of no-carrier-added $$^{177}$$Lu for radioimmunotherapy

渡辺 智; 橋本 和幸; 花岡 宏史*; 遠藤 啓吾*; 石岡 典子

JAEA-Review 2010-065, JAEA Takasaki Annual Report 2009, P. 109, 2011/01

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2010-065.pdf

がん治療に有用な$$beta$$線放出核種である$$^{177}$$Lu(半減期6.7日)の製造研究($$^{176}$$Yb(n,$$gamma$$)$$^{177}$$Yb(T$$_{1/2}$$=1.911h)$$rightarrow$$$$^{177}$$Lu)では、逆相シリカゲルカラム法による抗体標識が可能な高純度無担体$$^{177}$$Luの分離・精製法の開発に成功している。しかし、本法では、ターゲット物質であるYb$$_{2}$$O$$_{3}$$が2mg以上であると無担体Luを完全に分離することができないことが臨床応用に向けての$$^{177}$$Luの大量製造の課題であった。そこで、精密分離前に粗分離を行い、分離可能な最大ターゲット重量を検討した。その結果、固相抽出分離カラムによる粗分離の導入により、Yb$$_{2}$$O$$_{3}$$量が10mgまで分離可能であることを明らかにした。なお、Yb$$_{2}$$O$$_{3}$$量10mgは、JRR-3(中性子束1$$times$$10$$^{14}$$n$$cdot$$cm$$^{-2}$$s$$^{-1}$$)で10日間照射することにより3.6GBqの$$^{177}$$Lu(計算値)が生成するターゲット量に相当するので、臨床応用に必要なGBqオーダーの製造が本研究により理論上達成可能となった。今後は、固相抽出分離カラムと逆相シリカゲルカラム(精密分離)とを組合せ、GBqオーダーの高純度無担体$$^{177}$$Luの製造法の確立を目指す。

論文

PET studies of neuroendcrine tumors by using $$^{76}$$Br-$$m$$-bromobenzylguanidine ($$^{76}$$Br-MBBG)

渡邉 茂樹; 花岡 宏史*; Liang, J. X.*; 飯田 靖彦*; 渡辺 智; 遠藤 啓吾*; 石岡 典子

JAEA-Review 2010-065, JAEA Takasaki Annual Report 2009, P. 107, 2011/01

https://jopss.jaea.go.jp/pdfdata/JAEA-Review-2010-065.pdf

$$^{131}$$I-$$m$$-Iodobenzylgunanidine ($$^{131}$$I-MIBG), functional analogue of norepinephrine, has been employed for the therapy of neuroendcrine tumors which express norepinephrine transporter (NET). $$^{123}$$I-MIBG scintigraphy has been also used for diagnosis of NET positive tumors such as detecting metastasis, investigating suitability and monitoring response to the treatment with $$^{131}$$I-MIBG. However, $$^{123}$$I-MIBG scintigraphy has limitation to diagnose small legions due to its lower sensitivity and spatial resolution. Since positron emission tomography (PET) is superior to scintigraphy, positron emitter labeled MIBG has potential to improve diagnostic ability of NET positive neuroendcrine tumors. Then, we have reveal the utility of positron emitter $$^{76}$$Br labeled m-bromobenzylguanidine ($$^{76}$$Br-MBBG) as a PET tracer for NET positive tumor.

論文

PET imaging of norepinephrine transporter-expressing tumors using $$^{76}$$Br-${it meta}$-bromobenzylguanidine

渡邉 茂樹; 花岡 宏史*; Liang, J. X.; 飯田 靖彦*; 遠藤 啓吾*; 石岡 典子

Journal of Nuclear Medicine, 51(9), p.1472 - 1479, 2010/09

https://doi.org/10.2967/jnumed.110.075465
 被引用回数：21 パーセンタイル：56.09(Radiology, Nuclear Medicine & Medical Imaging)

${it Meta}$-iodobenzylguanidine (MIBG) labeled has been widely used for the diagnosis and radiotherapy of norepinephrine transporter (NET)-expressing tumors. This study demonstrated that a positron emitter $$^{76}$$Br labeled ${it meta}$-bromobenzylguanidine ($$^{76}$$Br-MBBG) was prepared and evaluated as a potential PET tracer for imaging NET-expressing tumors. $$^{76}$$Br-MBBG was stable in vitro, but some time-dependent dehalogenation was observed after administration in normal mice. MBBG showed high uptake in PC-12 tumor cells, and this uptake was significantly decreased by the addition of NET inhibitors. In biodistribution, MBBG showed high tumor accumulation (32.0 $$pm$$ 18.6% ID/g at 3 h p.i.) and the tumor-to-blood ratio reached as high as 54.4 $$pm$$ 31.9. Tumor uptake of MBBG correlated very well with that of $$^{125}$$I-MIBG (r = 0.997), but not with $$^{18}$$F-FDG. MBBG-PET showed a very clear image of the transplanted tumor with high sensitivity, and the visualized lesion was different from that by FDG-PET. These results indicated that $$^{76}$$Br-MBBG would be a potential PET tracer for imaging NET-expressing neuroendocrine tumors, and could provide useful information for determining the indications for $$^{131}$$I-MIBG therapy.

論文

Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with $$^{64}$$Cu-labeled trastuzumab PET

Paudyal, P.*; Paudyal, B.*; 花岡 宏史*; 織内 昇*; 飯田 靖彦*; 吉岡 弘樹*; 富永 英之*; 渡辺 智; 渡邉 茂樹; 石岡 典子; et al.

Cancer Science, 101(4), p.1045 - 1050, 2010/04

https://doi.org/10.1111/j.1349-7006.2010.01480.x
 被引用回数：40 パーセンタイル：67.45(Oncology)

Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of $$^{64}$$Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with $$^{64}$$Cu-DOTA-trastuzumab. PET studies revealed a significantly high accumulation of $$^{64}$$Cu-DOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 h and 48 h post-injection. $$^{64}$$Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy.

118 件中 1件目～20件目を表示